ALKERAN (melphalan) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Melphalan is leukemogenic in humans.
Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.
ALKERAN (melphalan), also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent which is active against selective human neoplastic diseases.
ALKERAN Tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Published Studies Related to Alkeran (Melphalan)
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. [2011.05]
OBJECTIVES: Bone disease is a key presenting feature of myeloma. This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs. MP in previously untreated myeloma patients assessed clinical bone disease events and changes in alkaline phosphatase (ALP), a marker for osteoblast activation, and serum Dickkopf-1 (DKK-1), an inhibitor of osteoblast differentiation, during treatment... CONCLUSIONS: These results suggest a positive effect of bortezomib on bone metabolism and potentially bone healing in myeloma. (c) 2011 John Wiley & Sons A/S.
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. [2011.04]
A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau... Vincristine-doxorubicin-dexamethasone/melphalan-prednisolone switch-induction therapy might be feasible and effective for Japanese patients with multiple myeloma.
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. [2011.04]
BACKGROUND: Explore safety and efficacy of three palonosetron-containing regimens for emesis prevention over 7 days in multiple myeloma (MM) patients receiving melphalan (100 mg/m(2)) and hematopoietic stem cell transplantation (HSCT)... CONCLUSIONS: Palonosetron with dexamethasone was safe and effective in preventing emesis in MM patients receiving melphalan and HSCT. This pilot study with a limited number of patients suggests that multiple doses of palonosetron could be more effective than a single dose in making patients emesis free without need for rescue medication. However, even multiple doses of palonosetron resulted in only 20% of patients being emesis free without rescue medication, suggesting that further improvement will require development of more effective combination antiemetic therapy. (c) The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. [2011.01]
The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules... Although patients treated with MPT were relatively younger and had more frequent RI, better responses and less early mortality were observed in all age groups despite more frequent discontinuation.
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. [2011.01]
OBJECTIVES: This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone... CONCLUSIONS: Rates of bortezomib-induced PN in the frontline setting were similar to those in relapsed patients and resolved in most cases. (c) 2010 John Wiley & Sons A/S.
Clinical Trials Related to Alkeran (Melphalan)
A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation [Recruiting]
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma [Recruiting]
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing.
Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of
chemotherapy. Giving chemotherapy with a peripheral stem cell transplant once or twice,
using stem cells from the patient or an identical brother or sister, may allow more
chemotherapy to be given so more cancer cells are killed. Giving maintenance therapy after a
stem cell transplant may kill any cancer cells that remain. It is not yet known which dose
of melphalan is more effective in treating multiple myeloma (MM).
PURPOSE: This randomized phase III trial is studying two different doses of melphalan to
compare how well they work when given together with amifostine followed by one or two
autologous or syngeneic stem cell transplants and maintenance therapy in treating patients
with stage II-III MM
Busulfan Plus Melphalan Versus Melphalan [Recruiting]
The goal of this clinical research study is to compare Busulfex (busulfan) with or without
Alkeran (melphalan) to learn which study therapy may be better at helping to control MM in
patients who will receive an autologous stem cell transplant. The safety of this
combination therapy will also be studied.
Melphalan and busulfan are designed to damage the DNA (genetic material) of cells, which may
cause cancer cells to die.
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older [Recruiting]
In this study the investigators are comparing this standard regimen to the newly established
regimen of melphalan and bortezomib.
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma [Recruiting]
The primary objective of this study is to evaluate the safety and tolerability of four dose
levels of liposomal doxorubicin, melphalan, and bortezomib in patients with
relapsed/refractory MM and to identify a maximum tolerated dose (MTD) of this combination.
Reports of Suspected Alkeran (Melphalan) Side Effects
White Blood Cell Count Decreased (15),
Myelodysplastic Syndrome (11),
Febrile Neutropenia (9),
Decreased Appetite (8),
Neoplasm Malignant (8),
Diarrhoea (8), more >>
Page last updated: 2011-12-09